Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Endothelial Tie1–mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis
Silvia La Porta, … , Soniya Savant, Hellmut G. Augustin
Silvia La Porta, … , Soniya Savant, Hellmut G. Augustin
Published January 22, 2018
Citation Information: J Clin Invest. 2018;128(2):834-845. https://doi.org/10.1172/JCI94674.
View: Text | PDF
Research Article Angiogenesis Oncology

Endothelial Tie1–mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis

  • Text
  • PDF
Abstract

The endothelial tyrosine kinase receptor Tie1 remains poorly characterized, largely owing to its orphan receptor status. Global Tie1 inactivation causes late embryonic lethality, thereby reflecting its importance during development. Tie1 also plays pivotal roles during pathologies such as atherosclerosis and tumorigenesis. In order to study the contribution of Tie1 to tumor progression and metastasis, we conditionally deleted Tie1 in endothelial cells at different stages of tumor growth and metastatic dissemination. Tie1 deletion during primary tumor growth in mice led to a decrease in microvessel density and an increase in mural cell coverage with improved vessel perfusion. Reduced angiogenesis and enhanced vascular normalization resulted in a progressive increase of intratumoral necrosis that caused a growth delay only at later stages of tumor progression. Concomitantly, surgical removal of the primary tumor decreased the number of circulating tumor cells, reduced metastasis, and prolonged overall survival. Additionally, Tie1 deletion in experimental murine metastasis models prevented extravasation of tumor cells into the lungs and reduced metastatic foci. Taken together, the data support Tie1 as a therapeutic target by defining its regulatory functions during angiogenesis and vascular abnormalization and identifying its role during metastasis.

Authors

Silvia La Porta, Lise Roth, Mahak Singhal, Carolin Mogler, Carleen Spegg, Benjamin Schieb, Xianghu Qu, Ralf H. Adams, H. Scott Baldwin, Soniya Savant, Hellmut G. Augustin

×

Figure 3

The intratumoral vasculature in Tie1iECKO mice progressively becomes antiangiogenic and normalizes over time during primary tumor growth.

Options: View larger image (or click on image) Download as PowerPoint
The intratumoral vasculature in Tie1iECKO mice progressively becomes ant...
(A–D) Quantification of vessel area (A), vessel density (B), and desmin-positive (C) and αSMA-positive (D) blood vessels 9 and 12 days after inoculation with LLC cells (n = 5). **P < 0.01 and *P < 0.05, by 2-tailed Mann-Whitney U test. (E and F) Quantification of primary tumor necrosis 9 and 12 days after inoculation of LLC cells (n = 5) (E) and analysis of the lectin-perfused vessel area (n = 5) (F). *P < 0.05, by 2-tailed Mann-Whitney U test. Error bars represent mean ± SD.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts